Flora Growth CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
ZeroStack Corp. has finalized a private cryptocurrency financing, acquiring 142,232,948 Zero Gravity (0G) blockchain tokens.
ZeroStack Corp. shareholders approved amendments to the 2022 Incentive Compensation Plan, increasing share availability and updating company name references.
ZeroStack Corp. announced the grant of stock options to its CEO, CFO, and Executive Chairman, with vesting tied to specific stock price performance milestones.
ZeroStack Corp. announced a series of strategic transactions including the acquisition of Texas Blocker Corp. via a share exchange and the settlement of a convertible note, aiming for U.S. domestic tax classification.
Flora Growth Corp. officially changed its corporate name to ZeroStack Corp. and its Nasdaq ticker symbol to ZSTK, effective January 29, 2026.
Flora Growth Corp. announced the appointment of Larry Zeifman as a new independent director and Audit Committee Chair, filling a previous vacancy, and Manfred Leventhal as Nominating Committee Chair.
Flora Growth Corp. has entered into a Note Settlement Agreement to fully satisfy its obligations under a convertible note by paying Solana, cash, and issuing common shares.
Flora Growth Corp. has finalized a separation agreement with former CEO Clifford Starke, including a cash payment and restricted share awards.
Flora Growth Corp. shareholders approved a significant increase in shares available for its 2022 Incentive Compensation Plan and other strategic proposals at a special meeting.
Flora Growth Corp. has entered into an agreement with White Lion Capital, LLC for up to $25 million in common share purchases to fund its digital asset strategy and general corporate purposes.
ZeroStack, a Flora Growth Corp. initiative, announced over $401 million in funding, the launch of its 0G token, and new leadership to drive its decentralized AI infrastructure.
Flora Growth Corp. filed a prospectus supplement to allow for the sale of up to an additional $3.45 million in common shares through its 'at the market' program.
Flora Growth Corp. has entered into an 'at-the-market' sales agreement with Revere Securities LLC to raise up to $2.12 million for general corporate purposes.
Flora Growth Corp. announced a significant strategic shift, divesting its cannabis business and raising over $400 million in cash and digital assets to fund a new digital asset treasury strategy focused on AI.
Flora Growth Corp. announced non-compliance with Nasdaq listing rules following the passing of independent director Harold Wolkin.
Flora Growth Corp. has completed a 1-for-39 reverse stock split, effective August 3, 2025, with post-split trading expected to commence on the Nasdaq Capital Market on August 4, 2025.
Flora Growth Corp. shareholders approved an increase in shares reserved for its 2022 Incentive Compensation Plan and the repricing of certain outstanding Stock Appreciation Rights, while notably rejecting a proposal for new SAR grants to executive officers.
Flora Growth Corp. has entered into a securities purchase agreement for a private placement, raising approximately $1.1 million to invest in cryptocurrencies and for general corporate purposes.
Flora Growth Corp. received a notice from Nasdaq stating that its common shares did not maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days, potentially leading to delisting.
Flora Growth Corp. has acquired United Beverage Distribution, a distributor of cannabis-infused drinks, through a share purchase agreement involving stock and promissory notes.
Flora Growth Corp. has granted a total of 1,235,000 Restricted Stock Awards and 440,000 Stock Appreciation Rights to its officers, directors, employees, and consultants.
Flora Growth Corp. has entered into a securities purchase agreement for a registered direct offering of 2,850,000 common shares, raising approximately $3.1 million in net proceeds.
Flora Growth Corp. has terminated its At-The-Market Issuance Sales Agreement with Aegis Capital Corp. effective December 12, 2024.
Flora Growth Corp. has entered into a placement agent agreement with Aegis Capital Corp. to facilitate a potential offering of up to $75 million in common shares, with an initial sale of 425,000 shares for approximately $709,750.
Flora Growth Corp. has appointed Sammy Dorf as Executive Chairman and Manfred Leventhal as an independent director, while Brendan Cahill has resigned from the board.
Flora Growth Corp. has entered into a new supply agreement with Northern Green Canada for medicinal cannabis products in the German market, replacing a previous agreement with a Curaleaf affiliate.
Flora Growth Corp. shareholders approved stock appreciation rights for the CEO and CFO at the annual meeting, with vesting tied to significant share price increases.
Flora Growth Corp. addressed a Nasdaq listing rule non-compliance issue by appointing a new independent director to its audit committee following a previous director's resignation.
Flora Growth Corp. held its 2024 Annual Meeting, where shareholders voted on the election of directors, appointment of auditors, and approval of amendments to the incentive plan and stock issuances.
Flora Growth Corp. has acquired Australian Vaporizers Pty Ltd. for 550,000 of its common shares, valued at $0.7 million.